Orantinib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameOrantinib
Drug Alias Nameorantini奥兰替尼orantinibum奥安替尼orantinib +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsPlatelet-derived growth factor receptor beta inhibitorsFibroblast growth factor receptor 1 antagonists
TargetsVascular endothelial growth factor receptor 2Platelet-derived growth factor receptor betaFibroblast growth factor receptor 1
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsProstatic Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanSouth Korea +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteTaiho Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursKidney NeoplasmsProstatic Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksN/A